BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34801997)

  • 21. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation.
    Lee ES; Shen Q; Pitts RL; Guo M; Wu MH; Sun SC; Yuan SY
    J Vasc Surg; 2011 Aug; 54(2):454-9; discussion 459-60. PubMed ID: 21620625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected Metal Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases as Potential Biomarkers for Tubulointerstitial Fibrosis in Children with Unilateral Hydronephrosis.
    Bieniaś B; Sikora P
    Dis Markers; 2020; 2020():9520309. PubMed ID: 32670438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
    Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
    Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
    Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.
    Gluba-Brzózka A; Michalska-Kasiczak M; Franczyk B; Nocuń M; Toth P; Banach M; Rysz J
    Lipids Health Dis; 2016 Feb; 15():22. PubMed ID: 26843213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
    Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of surgery on the levels of matrix metalloproteinases in patients with inguinal hernia.
    Strohalmová S; Levová K; Kuběna AA; Krška Z; Hoskovec D; Zima T; Kalousová M
    Physiol Res; 2021 Aug; 70(4):627-634. PubMed ID: 34062071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders.
    Hurnaus S; Mueller-Felber W; Pongratz D; Schoser BG
    Eur Neurol; 2006; 55(4):204-8. PubMed ID: 16772717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia.
    Beaudeux JL; Giral P; Bruckert E; Bernard M; Foglietti MJ; Chapman MJ
    Atherosclerosis; 2003 Jul; 169(1):139-46. PubMed ID: 12860260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.
    Nissi R; Talvensaari-Mattila A; Kotila V; Niinimäki M; Järvelä I; Turpeenniemi-Hujanen T
    Reprod Biol Endocrinol; 2013 Jan; 11():2. PubMed ID: 23320481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy.
    Sekiuchi M; Kudo A; Nakabayashi K; Kanai-Azuma M; Akimoto Y; Kawakami H; Yamada A
    Clin Exp Nephrol; 2012 Dec; 16(6):863-74. PubMed ID: 22614167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
    Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.
    Xing Y; Shepherd N; Lan J; Li W; Rane S; Gupta SK; Zhang S; Dong J; Yu Q
    Brain Behav Immun; 2017 Oct; 65():161-172. PubMed ID: 28487203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.